| Bioactivity | KDM2B-IN-2, a potent histone demethylase (kdm2b) inhibitor with an IC50 of 0.021 μM in a KDM2B TR-FRET assay. KDM2B-IN-2 can be used for hyperproliferative diseases research[1]. | ||||||||||||
| Name | KDM2B-IN-2 | ||||||||||||
| CAS | 1965248-01-4 | ||||||||||||
| Formula | C21H26N4O2S2 | ||||||||||||
| Molar Mass | 430.59 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Brian K. Albrecht, et al. 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors. Patent WO2016112251A1. |
KDM2B-IN-2
CAS: 1965248-01-4 F: C21H26N4O2S2 W: 430.59
KDM2B-IN-2, a potent histone demethylase (kdm2b) inhibitor with an IC50 of 0.021 μM in a KDM2B TR-FRET assay. KDM2B-IN-
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.